Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

Marcellin, Patrick; Buti, Maria; Krastev, Zahari; de Man, Robert; Zeuzem, Stefan; Lou, Lillian; Gaggar, Anuj; Flaherty, John; Massetto, Benedetta; Lin, Lanjia; Dinh, Phillip; Subramanian, G.; McHutchison, John; Flisiak, Robert; GÜREL, SELİM; Dusheiko, Geoffrey; Heathcote, E.

doi:10.1016/j.jhep.2014.07.019

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

Atıf İçin Kopyala

Marcellin P., Buti M., Krastev Z., de Man R. A., Zeuzem S., Lou L., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.61, sa.6, ss.1228-1237, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 61 Sayı: 6
Basım Tarihi: 2014
Doi Numarası: 10.1016/j.jhep.2014.07.019
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1228-1237
Anahtar Kelimeler: Chronic hepatitis B, Hepatitis B surface antigen, Tenofovir disoproxil fumarate, SUSTAINED VIROLOGICAL RESPONSE, POLYMERASE CHAIN-REACTION, TERM-FOLLOW-UP, PEGINTERFERON ALPHA-2A, NUCLEOS(T)IDE ANALOG, NEGATIVE PATIENTS, HBSAG LOSS, VIRUS-DNA, SERUM, THERAPY
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background & Aims: In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment. HBsAg kinetics in patients with and without HBsAg loss and predictors of HBsAg loss were evaluated.